B6-huIL18BP Mouse
Product Name
B6-huIL18BP Mouse
Product ID
C001869
Strain Name
C57BL/6NCya-Il18bptm1(hIL18BP)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “B6-huIL18BP Mouse (Catalog C001869) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
IL18BP
Gene Alias
FVH, IL18BPa
NCBI ID
Chromosome
Chr 11 (Human)
MGI ID
Datasheet
Strain Description
The IL18BP (Interleukin 18 Binding Protein) gene encodes a secreted, high-affinity, naturally occurring antagonist of the proinflammatory cytokine Interleukin-18 (IL-18), functioning by binding IL-18 to prevent it from interacting with its receptor, thereby inhibiting IL-18-induced immune responses, such as interferon-gamma (IFN-γ) production [1]. The gene's protein, IL-18BP, is constitutively expressed and secreted primarily by mononuclear cells (such as monocytes/macrophages and T-cells) and is widely expressed at the RNA level in numerous tissues, including the spleen, lung, placenta, and small intestine [2]. Its expression can be enhanced by IFN-γ in a negative feedback loop to regulate inflammation [3]. Dysregulation or an imbalance in the ratio of IL-18 to IL-18BP is associated with a range of inflammatory and autoimmune conditions, including Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), systemic juvenile idiopathic arthritis (SJIA), fulminant viral hepatitis, and adult-onset Still's disease.
The B6-huIL18BP mouse is a humanized model constructed through gene-editing technology, in which the sequences from the ATG start codon to the TAA stop codon of the endogenous mouse Il18bp gene are replaced with the sequences from the ATG start codon to the TAA stop codon of the human IL18BP gene. This model can be used for research on tumor mechanisms and tumor immunotherapy, inflammatory and autoimmune conditions, as well as for the development of IL18BP-targeted drugs.
Reference
Park SY, Hisham Y, Shin HM, Yeom SC, Kim S. Interleukin-18 Binding Protein in Immune Regulation and Autoimmune Diseases. Biomedicines. 2022 Jul 20;10(7):1750.
Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013 Oct 8;4:289. doi: 10.3389/fimmu.2013.00289.
Paulukat J, Bosmann M, Nold M, Garkisch S, Kämpfer H, Frank S, Raedle J, Zeuzem S, Pfeilschifter J, Mühl H. Expression and release of IL-18 binding protein in response to IFN-gamma. J Immunol. 2001 Dec 15;167(12):7038-43.
Strain Strategy
The sequences from the ATG start codon to the TAA stop codon of the endogenous mouse Il18bp gene were replaced with the sequences from the ATG start codon to the TAA stop codon of the human IL18BP gene.
Figure 1. Gene editing strategy for B6-huIL18BP mice.
Application Area
Screening, development, and pre-clinical evaluation of IL18BP-targeted drugs;
Research on the interaction between metabolism and inflammation and the regulation of the tumor immune microenvironment;
Research on various inflammatory and autoimmune diseases such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), systemic juvenile idiopathic arthritis (SJIA), fulminant viral hepatitis, and adult Still's disease.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.